KRAS and adenocarcinoma: Single amino acid substitutions involving codons 12, 13 and 61 of KRAS were identified in 23 of 130 NSCLC (17.7%) overall (18 of 93 adenocarcinomas (19%) and five of 18 NSCLC-NOS (27.7%)) (Table 3).